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ABSTRACT
Background The value of quantitative CT (QCT) to
identify chronic obstructive pulmonary disease (COPD)
phenotypes is increasingly appreciated. The authors
hypothesised that QCT-defined emphysema and airway
abnormalities relate to St George’s Respiratory
Questionnaire (SGRQ) and Body-Mass Index, Airflow
Obstruction, Dyspnea and Exercise Capacity Index
(BODE).
Methods 1200 COPDGene subjects meeting Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria for COPD with QCT analysis were included. Total
lung emphysema was measured using the density mask
technique with a 950 Hounsfield unit threshold. An
automated programme measured mean wall thickness
(WT), wall area percentage (WA%) and 10 mm lumenal
perimeter (pi10) in six segmental bronchi. Separate
multivariate analyses examined the relative influence of
airway measures and emphysema on SGRQ and BODE.
Results In separate models predicting SGRQ score, a 1
unit SD increase in each airway measure predicted higher
SGRQ scores (for WT, 1.90 points higher, p¼0.002; for
WA%, 1.52 points higher, p¼0.02; for pi10, 2.83 points
higher p<0.001). The comparable increase in SGRQ for
a 1 unit SD increase in emphysema percentage in these
models was relatively weaker, significant only in the pi10
model (for emphysema percentage, 1.45 points higher,
p¼0.01). In separate models predicting BODE, a 1 unit
SD increase in each airway measure predicted higher
BODE scores (for WT, 1.07-fold increase, p<0.001; for
WA%, 1.20-fold increase, p<0.001; for pi10, 1.16-fold
increase, p<0.001). In these models, emphysema more
strongly influenced BODE (range 1.24e1.26-fold increase,
p<0.001).
Conclusion Emphysema and airway disease both relate
to clinically important parameters. The relative influence
of airway disease is greater for SGRQ; the relative
influence of emphysema is greater for BODE.
INTRODUCTION
The importance of identifying distinct phenotypes
within chronic obstructive pulmonary disease
(COPD) is becoming increasingly appreciated, for
the purpose of establishing prognosis and for
identifying appropriate patients for therapies.1
Although multiple methods for describing the
heterogeneity intrinsic to this disease have been
developed, quantitative CT (QCT) may have
significant value as a non-invasive means to iden-
tify distinct phenotypes in COPD. To establish the
validity of COPD phenotyping based on QCT
characteristics, correlations must be made in large
groups of comprehensively assessed patients with
COPD. We have previously reported that CT
measures of emphysema and airways disease relate
to COPD exacerbation frequency, a significant
disease outcome for patients with COPD.2 The
relationship between QCT phenotype and other
important patient-centred outcomes is unknown.
In this study, we describe a comprehensive evalua-
tion of 1200 patients with COPD who underwent
clinical, physiological and radiological evaluation
with the goal of assessing the relationship between
QCT-defined emphysema severity, airway abnor-
mality and clinically relevant outcomes, including
St George’s Respiratory Questionnaire (SGRQ) and
the BODE index.3 4
METHODS
Patient selection
The COPDGene Study is a National Heart Lung
Blood Institute funded multicentre investigation to
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examine the genetic epidemiology of smoking-related lung
disease. Patients were selected for participation in the study
based on the following criteria: age 45e80 years, non-smoker or
cigarette smoking $10 pack years, and willingness to undergo
study-related testing that included spirometry, CT scan of the
chest, and blood collection for biomarker and genetic analysis. In
our analysis patients were selected from the first 2500 dataset
from the COPDGene study, April 2010, and included 1200
patients who met GOLD criteria5 for stages 1e4 fixed airflow
obstruction with a post-bronchodilator forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) ratio #0.7 and
additionally had complete QCT-based emphysema and airway
analyses available. Our analyses included all 1200 patients
except for the BODE analyses, which included a smaller subset
of 1179 patients who had complete data available to calculate
the BODE index. All participants provided written informed
consent. This research protocol was approved by the institu-
tional review board at each participating institution.
Data collection and exacerbation determination
Demographical data, smoking and medical history were
collected via interview or self-administered questionnaires.
Dyspnoea was quantified using the modified Medical Research
Council dyspnoea scale (MMRC),6 which is a five-point scale
that asks respondents to rate dyspnoea from 0 (absent) to 4
(dyspnoea when dressing/undressing). The SGRQ is a health-
related quality of life (HRQL), obstructive lung disease-specific
instrument with three domains (symptoms, activities and
impact), all scored from 0 to 100. Higher scores correspond to
worse HRQL.3 All patients underwent the standard 6-min walk
distance (6MWD) test. The BODE index was calculated using
6MWD, FEV1 % predicted, MMRC and body mass index (BMI),
as previously described.7
Physiological testing
Patients underwent spirometry before and after the adminis-
tration of short acting bronchodilating medication (albuterol).
All spirometric tracings were independently reviewed to ensure
that ATS criteria were met.8
Imaging
Objective analysis of the lung parenchyma and airways was
performed on volumetric CT scans of the chest obtained at full
inflation. All CT scans were obtained under a standardised
protocol.2 Parenchymal analysis and airway analyses were
performed using VIDA Pulmonary Workstation 2 (http://www.
vidadiagnostics.com). Lung area with a CT attenuation value of
less than 950 Hounsfield Units (HU) on the inspiratory scan
was considered to be emphysematous tissue. Reconstruction of
CT inspiratory images allowed for estimation of total lung
capacity (TLC). TLC % predicted was calculated based on
a previously published equation.9 Airway morphology was
examined in six segmental airways: apical segment, right upper
lobe (RB1), lateral segment, right middle lobe (RB4), posterior
basal segment, right lower lobe (RB10), apicoposterior segment,
left upper lobe (LB1), superior lingular segment (LB4), and
posterior basal segment, left lower lobe (LB10).10 CT-based
metrics of airway disease included mean bronchial wall thick-
ness calculated as an average of the six segmental values for each
patient, wall area percentage (WA%) (100*WA/total bronchial
area)11 obtained at the same sites as those used for bronchial
wall thickness, and the square root of the wall area of a theo-
retical airway of 10 mm lumenal perimeter (Pi10), as previously
described.12 13
Statistical analyses
All statistical analyses were conducted with the SAS statistical
analysis package (V.9.2; SAS Institute Inc). For univariate and
multivariate analyses, data are presented for ‘normalised’ and
‘unnormalised’ radiological parameters. For ‘normalised’ radio-
logical parameters, airway disease measures and emphysema
values have been scaled and centred as follows: (value e mean)/
SD. Hence a 1 unit increase in a normalised measure is 1 SD. For
SGRQ total score, multivariate linear regression models were
used, adjusted for age, gender, current smoking status, height,
FEV1 % predicted and scanner type. For BODE, zero-inflated
Poisson regression was used, adjusted for age, gender, smoking
status and scanner type. This model is more appropriate as the
BODE distribution of values in this cohort was skewed, with
more patients displaying lower BODE scores (see figure 1). p
Values <0.05 were considered to be statistically significant. The
three-dimensional, smoothed surface plots of the raw data
(figure 2A,C) were created with SAS V.9.2 statistical software,
using PROC G3GRID, which uses spline interpolation as the
smoothing algorithm. The density plots of the raw data (figure
2B,D) were also created with SAS V.9.2 statistical software,
using PROC KDE, which utilises a non-parametric technique for
density estimation.
RESULTS
Data from 1200 patients were available for analysis. Their
demographical and physiological data are outlined in table 1.
This dataset is roughly split between men and women. The
majority were ex-smokers (63.2%) with moderate COPD by
spirometric criteria, median FEV1 % predicted 56%. A broad
range of disease severity as defined by BODE and SGRQ were
also present (see figure 1).
In univariate models, airway measures and emphysema
demonstrated statistically significant associations with BODE
and SGRQ (see table 2), except segmental wall thickness which
did not show a statistically significant relationship with BODE.
Because the units for each of these radiological predictors differs
widely with respect to the range of values seen in the popula-
tion, a better interpretation of the relative importance of each
can be seen with the normalised parameter estimates, which are
also displayed in table 2. For normalised estimates, a 1 unit
change corresponds to 1 SD change for that variable. When
examining the normalised estimates, the strongest signal for
SGRQ is seen for pi10. The strongest signal for BODE is seen
with emphysema percentage.
To visualise the relationships between pi10 and emphysema
with respect to SGRQ, a three-dimensional plot was created
(figure 2A), which demonstrates that regardless of emphysema
extent, increasing pi10 is associated with increasing SGRQ score.
Similarly, increasing emphysema is also associated with
increasing SGRQ score regardless of pi10. To understand these
relationships further, we selected patients in approximately the
highest 10th percentile of SGRQ scores and created density plots
depicting the relationship between emphysema and airway
measures (figure 2B). Although a wide range of pi10 and
emphysema values are still represented, for the highest density
of patients depicted in red, normalised pi10 values were higher
than the average pi10 (3.78) whereas emphysema values were
lower than the group average for emphysema (13.9%).
By contrast, a similar three-dimensional plot for BODE (figure
2C), showing the independent relationship between pi10,
emphysema and BODE revealed that even at extreme values of
pi10 in the absence of emphysema, increases in BODE are
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modest. A density plot for patients with approximately the 10th
highest percentile BODE scores is depicted in figure 2D. While
a wide range of pi10 and emphysema values are present, the
highest density of patients in red have a much greater amount of
emphysema than either the group mean (13.9%) or patients
with SGRQ scores in figure 2B, whereas pi10 values are similar
to the group mean (3.78) but lower than patients with high
SGRQ scores in figure 2B. Additional density plots by airway
measure for the entire cohort are presented in online supple-
mental figures S1eS3.
Further analysis of the relationships between airway disease
measures, emphysema, SGRQ and BODE was carried out via
Figure 1 Frequency distribution of
BODE index scores (left panel) and St
George’s Respiratory Questionnaire
(SGRQ) total scores (right panel).
Figure 2 (A) Three-dimensional plot demonstrating the relationship between increasing 10 mm lumenal perimeter (pi10), emphysema percentage
and St George’s Respiratory Questionnaire (SGRQ) score. (B) Density plot of patients with chronic obstructive pulmonary disease (COPD) with SGRQ
score approximately in the 90th percentile (score $64, n¼146) demonstrating degree of pi10 and emphysema in this subgroup. High density in red,
low density in blue. (C) Three-dimensional plot demonstrating the relationship between increasing pi10, emphysema percentage and BODE index score.
(D) Density plot of patients with COPD with BODE score approximately in the 90th percentile (score$6, n¼142) demonstrating the degree of pi10 and
emphysema in this subgroup. High density in red, low density in blue.
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individual multivariate models including each airway disease
measure separately to compare their relative effect on emphy-
sema, adjusting for other relevant confounders. The results of
analyses predicting SGRQ are presented in tables 3 and 4. In
table 4, radiological predictors are normalised so that the relative
importance of airway measures in emphysema can be compared.
Table 3 shows that each airway parameter significantly
predicts increasing SGRQ score, with emphysema percentage
also being accounted for. A 1 mm increase in segmental wall
thickness results in an 8.49-point increase in SGRQ score (95%
CI 3.19 to 13.79; p¼0.002); a 1% increase in WA% results in
a 0.47-point increase in SGRQ (95% CI 0.08 to 0.85; p¼0.02); a 1
unit increase in pi10 results in a 22.13-point increase in SGRQ
(95% CI 12.99 to 31.29; p<0.001). Only in the model utilising
pi10 is emphysema statistically significant, and a positive asso-
ciation between increasing emphysema and greater SGRQ score
can be seen. Table 4 further emphasises the relative importance
of airway parameters to emphysema in predicting SGRQ as the
normalised airway estimates are all significantly larger than the
emphysema estimates. A 1 unit SD increase in segmental wall
thickness results in a 1.90-point increase in SGRQ score (95% CI
0.72 to 3.09; p¼0.002); a 1 unit SD increase in WA% results in
a 1.52-point increase in SGRQ (95% CI 0.27 to 2.76; p¼0.02); a 1
SD unit increase in pi10 results in a 2.83-point increase in SGRQ
(95% CI 1.66 to 4.00; p<0.001). In the model using pi10, a 1 unit
SD increase in emphysema results in a 1.45-point increase in
SGRQ (95% CI 0.33 to 2.57; p¼0.02). As all parameters in table 4
are for a SD change for that predictor, the scale of change for
each predictor in all models is comparable. To ensure differences
in full inspiratory capacity did not bias results, TLC % predicted
calculated from the CTwas also added to tables 3 and 4 models
but did not demonstrate any significant change in results (data
not shown).
Additional multivariate models for SGRQ subscores using
normalised pi10 and emphysema measures are presented in
online supplemental table 1. This analysis demonstrates that the
strongest relationship for radiological parameters exists with the
activity subscore. A 1 unit SD increase for pi10 results in a 3.38-
point increase in SGRQ activity subscore (95% CI 1.91 to 4.84;
p<0.001), and a 1 unit SD increase in emphysema results in
a 3.06-point increase in activity subscore (95% CI 1.54 to 4.60;
p<0.001.
Multivariate analyses for predicting BODE index are reported
in tables 5 and 6, for unnormalised and normalised radiological
parameters respectively. In table 5, each of the three airway
parameters predict increasing BODE index when additionally
adjusted for emphysema. A 1 mm increase in segmental wall
thickness results in a 1.36-fold increase in BODE index score
(95% CI 1.14 to 1.62; p<0.001); a 1% increase in WA% results in
a 1.06-fold increase in BODE index score (95% CI 1.05 to 1.07;
p<0.001); a 1 unit increase in pi10 results in a 3.30-fold increase
in BODE index score (95% CI 2.48 to 4.40; p<0.001). In all three
models, an increase in emphysema is also associated with
approximately a 1.02-fold increase in BODE index score
(p<0.001 for all models). Once again, all parameters in table 6
are for a SD change in that predictor so that the scale of change
for each predictor in all models is comparable. Here we see that,
in contrast to the model for SGRQ, the emphysema parameter is
larger than the airway parameters for every model and is
statistically significant.
The fold increase in BODE score for a 1 SD increase in
emphysema ranges between 1.24 and 1.26 (p<0.001) in all three
models, exceeding the upper bound of the 95% CI for the fold
Table 1 Baseline demographical and physiological data
Median (IQR)
Patients, n 1200
Men, %* 53.3
Current smoker, %* 36.8
Age, years 65.0 (47.9, 70.6)
FEV1 % predicted 56 (38, 74)
FEV1/FVC 0.53 (0.40, 0.63)
Pack-years 46 (35, 68)
Body mass index, kg/m2 27.1 (23.5, 31.1)
6-min walk distance, m 381 (288, 470)
MMRC 2 (0, 3)
BODE index score 2 (1, 4)
SGRQ total score 35.3 (17.2, 52.3)
Emphysema, % 9.7 (3.6, 21.2)
Segmental bronchial wall thickness, mm 1.55 (1.44, 1.68)
Segmental wall area % 62.34 (60.32, 64.45)
Pi10 3.46 (3.69, 3.84)
*Reported as mean percentage and not median.
MMRC, modified Medical Research Council dyspnoea scale; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; Pi10, 10 mm lumenal
perimeter; SGRQ, St George’s Respiratory Questionnaire.
Table 2 Univariate associations between unnormalised and normalised radiological parameters, St
George’s Respiratory Questionnaire (SGRQ) total score and BODE
Unnormalised parameter
estimate (95% CI)
Normalised parameter
estimate (95% CI) p Valuey
SGRQ*
Emphysema, % 0.53 (0.45 to 0.61) 5.82 (4.91 to 6.72) <0.001
Segmental wall thickness, mm 8.72 (2.91 to 14.53) 1.95 (0.65 to 3.25) 0.003
Segmental wall area, % 1.96 (1.57 to 2.35) 6.27 (5.02 to 7.52) <0.001
Pi10 56.28 (46.91 to 65.64) 7.20 (6.00 to 8.40) <0.001
BODE*
Emphysema, % 1.02 (1.02 to 1.02) 1.23 (1.20 to 1.26) <0.001
Segmental wall thickness, mm 1.10 (0.93 to 1.29) 1.02 (0.99 to 1.06) 0.27
Segmental wall area, % 1.03 (1.02 to 1.05) 1.11 (1.07 to 1.16) <0.001
Pi10 2.20 (1.66 to 2.91) 1.11 (1.07 to 1.15) <0.001
*For SGRQ models, parameter estimate is the increase in SGRQ score for a 1 unit increase in unnormalised radiological parameter. For
BODE models, parameter estimate is the fold increase in BODE index score for a 1 unit increase in the unnormalised radiological
parameter. All models are adjusted for scanner type. For normalised radiological parameters, airway disease measures and
emphysema values have been scaled and centred as follows: (value e mean)/SD. Hence a 1 unit increase in a normalised measure is
1 SD.
yp Value for significance of parameter estimate in the model which is identical for unnormalised and normalised estimates.
Pi10, 10 mm lumenal perimeter.
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changes seen in airway parameters. The relative weight for the
three airway parameters is less, yet still independently predictive
when adjusted for emphysema. A 1 unit SD increase in
segmental wall thickness results in a 1.07-fold increase in BODE
index score (p<0.001), a 1 unit SD increase in segmental WA%
results in a 1.20-fold increase in BODE index score (p<0.001); a 1
unit SD increase in pi10 results in a 1.16-fold increase in BODE
index score (p<0.001). To correct for differences in inspiratory
capacity during the imaging maneuver, tables 5 and 6 models
were additionally adjusted for TLC % predicted that was
calculated from reconstruction of inspiratory CT images. This
did not result in a significant change in results (data not shown).
To better understand the relationship between radiological
parameters and BODE components, Spearman’s correlations
were performed between radiological parameters and BODE
components. These results are displayed in online supplemental
table 2. Emphysema correlates most strongly with FEV1%
predicted (r¼0.54, p<0.001). Pi10 correlates most strongly
with FEV1% predicted, r¼0.37, p<0.001. Online supplemental
table 3 displays additional analyses subdividing the cohort based
on presence ($75th percentile) or absence (#25th percentile) of
emphysema and airways disease (using pi10 as a representative
airway metric). These analyses further highlight the relationship
between increasing emphysema and BODE, and increasing
airway disease and SGRQ.
DISCUSSION
The results of this study establish a relationship between QCT
metrics and two indices of disease impact, a specific measure of
respiratory health status (SGRQ) and a multidimensional index
of COPD severity, BODE, that has been correlated with
mortality. In multivariate models, increases in both QCT
measures of airway disease and emphysema were associated
with higher SGRQ and BODE scores. However, in models that
were centred and scaled so that the relative weight of airway
disease measures and of emphysema measures could be
compared, a 1 unit SD increase in airway disease measures had
a greater relative effect on increasing SGRQ total score than a 1
unit SD increase in emphysema. In contrast, a similar analysis
performed on the BODE index indicated a greater relative
increase in BODE index scores for a 1 unit SD increase in
emphysema as opposed to airway measures. The colour-coded
density plots of patients with high SGRQ and BODE scores also
emphasise that an airway disease predominant phenotype is
associated with more impaired higher SGRQ whereas an
emphysema predominant phenotype is associated with higher
BODE index scores.
This analysis extends the findings of other studies on the
association between QCT measures of airway disease and
symptoms in COPD. In a prior report of the COPDGene cohort,
segmental airway wall thickening but not emphysema was
associated with the presence of cough and sputum.14 Grydeland,
et al reported that in COPD, both pi10 and emphysema were
related to dyspnoea, but only pi10 was associated with cough
and wheeze.15 Here we broaden these findings by examining the
relationships between QCT measures and SGRQ. While cough,
phlegm production and shortness of breath are all important
items assessed by the SGRQ, the SGRQ is an important inde-
pendent measure of HRQL in COPD.3 In this study, we help to
demonstrate a significant relationship between increasing
airways disease and emphysema with SGRQ, but also through
normalising the QCT parameters, demonstrate that the relative
influence of airway disease on SGRQ is significantly stronger
than that of emphysema.
While univariate analysis suggests a relationship between
disease severity as quantified by emphysema and SGRQ score
does exist, the multivariate analyses data suggest that airway
disease plays the relatively stronger role. In our multivariate
analysis, a 0.20-point increase in pi10 would correlate with
a four-point increase in SGRQ, the generally accepted minimal
important difference for SGRQ.16 The relationship between pi10
and the activity subscore of the SGRQ appears to be the
strongest. A ready explanation for this is not obvious, although
it may be that patients who have more significant airway
disease represent a unique subgroup of patients who, due to
pulmonary physiology or comorbid conditions, experience
greater decrements in functional status. The current results
differ from our prior analysis of 156 patients with COPD, which
Table 3 Multivariate analysis predicting St George’s Respiratory Questionnaire (SGRQ) total score using
unnormalised radiological parameters* (n¼1200)
Airway disease measure Airway parameter (95% CI) Emphysema % parameter (95% CI)
Segmental wall thickness, mm 8.49 (3.19 to 13.79), p¼0.002 0.08 (0.02 to 0.18), p¼0.13
Segmental wall area, % 0.47 (0.08 to 0.85), p¼0.02 0.10 (0.001 to 0.21), p¼0.05
Pi10 22.13 (12.99 to 31.29), p<0.001 0.13 (0.03 to 0.23), p¼0.01
*Models additionally adjusted for age, gender, height, forced expiratory volume in 1 s % predicted, current smoking status and scanner
type. Parameter estimate is the increase in SGRQ score for a 1 unit increase in radiological parameter. For normalised radiological
parameters, airway disease measures and emphysema values have been scaled and centred as follows: (value e mean)/SD. Hence
a 1 unit increase in a normalised measure is 1 SD.
Pi10, 10 mm lumenal perimeter.
Table 4 Multivariate analysis of St George’s Respiratory Questionnaire (SGRQ) total score using
normalised radiological parameters* (n¼1200)
Airway disease measure Airway parameter (95% CI) Emphysema % parameter (95% CI)
Segmental wall thickness, mm 1.90 (0.72 to 3.09), p¼0.002 0.83 (0.26 to 1.93), p¼0.13
Segmental wall area, % 1.52 (0.27 to 2.76), p¼0.02 1.14 (0.02 to 2.30), p¼0.05
Pi10 2.83 (1.66 to 4.00), p<0.001 1.45 (0.33 to 2.57), p¼0.01
*Models additionally adjusted for age, gender, height, FEV1% predicted, current smoking status and scanner type. Parameter estimate
is the increase in SGRQ score for a one unit increase in radiologic parameter. For normalised radiologic parameters, airway disease
measures and emphysema values have been scaled and centred as follows: (value e mean)/SD. Hence a one unit increase in
a normalised measure is one SD.
Pi10, 10 mm lumenal perimeter.
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demonstrated a relationship between increasing emphysema and
SGRQ score but not right upper lobe WA%.17 However, that
cohort was very small and composed of a unique study popula-
tion who were being evaluated for lung surgery (tumour resec-
tion, lung volume reduction surgery or lung transplantation).
This current analysis is significantly larger and includes a more
representative sample of the general COPD population.
While we and others have documented a relationship between
QCTemphysema measures and BODE score,17 18 in this analysis
we demonstrated a relationship between airway disease
measures and BODE score and between emphysema and BODE
score. However, we are also able to examine the relative rela-
tionship between airway disease, emphysema and BODE. The
relationship between emphysema and BODE is stronger than
the relationship between airway disease and BODE. This is
suggested by the relative weight of the normalised parameter
estimates in the multivariate models (table 6) and the density
plot (figure 2D), in which it is evident that patients with high
BODE scores have a much greater burden of emphysema than
airway disease. To put this in perspective, our multivariate
analysis suggests that a 10% increase in emphysema would
correlate with a 1.23-fold increase in BODE score. While an
Minimal Important Difference (MID) for BODE is difficult to
define with certainty, a 1.19-fold increase in BODE has been
reported with pulmonary rehabilitation, which was also asso-
ciated with improved survival.19
The relationship between emphysema and BODE appears to
be driven most strongly by its relationship with FEV1, but not
surprisingly significant relationships between emphysema and
the other BODE components including BMI, MMRC and
6MWD are also seen. Weight loss20 and hyperinflation21 are
known associations with emphysema that likely contribute to
these relationships.
Previously we reported no significant relationship between
airway disease as measured by right upper lobe WA% and
BODE. However, this prior analysis was performed on a small,
highly selected COPD cohort compared with the significantly
larger cohort described here and also used a very localised
measure of airway disease (right upper lobe) as opposed to the
measures used here that are averaged from six separate bronchial
segments throughout the lung.
This analysis also demonstrates that three of the QCTairway
measures currently in use do not behave identically in multivar-
iate modelling. Currently no gold standard airway disease
measure has been identified and hence all three are included here.
As derivation of the airway measures differs significantly, it is
reasonable to expect that they each may contribute different
information. For instance, because WA% reflects wall thickness
relative to airway size, that measure will not be changed if both
elements increase. WA% and pi10 also have a stronger relation-
ship with FEV1 than wall thickness. Determining the airway
measure that best characterises patients with COPD is certainly
an issue that deserves further attention so that we can better
understand which aspects of airway dimensions relate to char-
acteristics intrinsic to normal development as opposed to disease.
These data also raise several questions about the interplay
between QCT phenotypes and clinical descriptors of disease.
The SGRQ was developed and has been tested in large numbers
of patients and can safely be assumed to be a valid indicator of
quality of life in patients with COPD with a wide variety of
phenotypes. However, our data suggest that the relationship
between SGRQ and pathological abnormality is complex as
SGRQ appears to be more influenced by changes in airway
disease than emphysema. Hence therapies targeted at different
aspects of the disease may result in different relative changes in
SGRQ, which should be considered when planning clinical trials
and determining appropriate outcome measures. Hypothetically
speaking, a therapy targeted at slowing emphysema, for
instance, may not be expected to have the same influence on
SGRQ as therapies targeted at airways disease. While improving
quality of life for patients with COPD is an important goal in
itself, these data underscore the complexity of inferring a rela-
tionship between SGRQ and disease pathology in patient
populations that are not well phenotyped.
Table 6 Multivariate analysis of BODE index score using normalised radiological parameters* (n¼1179)
Airway disease measure
Airway parameter estimate expressed
as fold change in BODE normalised
Emphysema % parameter estimate
expressed as fold change in BODE
normalised
Segmental wall thickness, mm 1.07 (1.03 to 1.11), p<0.001 1.24 (1.20 to 1.27), p<0.001
Segmental wall area, % 1.20 (1.15 to 1.25), p<0.001 1.26 (1.23 to 1.30), p<0.001
Pi10 1.16 (1.12 to 1.21), p<0.001 1.25 (1.21 to 1.29), p<0.001
*Model additionally adjusted for age, gender, current smoking status, and scanner type. Parameter estimate is the fold change in
BODE index score for a 1 unit increase in radiological parameter. For normalised radiological parameters, airway disease measures
and emphysema values have been scaled and centred as follows: (value e mean)/SD. Hence a 1 unit increase in a normalized measure
is 1 SD.
Pi10, 10 mm lumenal perimeter.
Table 5 Multivariate analysis predicting BODE index score using unnormalised radiological parameters*
(n¼1179)
Airway disease measure
Airway parameter estimate expressed
as fold change in BODE (95% CI)
Emphysema % parameter estimate
expressed as fold change in BODE
(95% CI)
Segmental wall thickness, mm 1.36 (1.14 to 1.62), p<0.001 1.02 (1.02 to 1.02), p<0.001
Segmental wall area, % 1.06 (1.05 to 1.07), p<0.001 1.02 (1.02 to 1.02), p<0.001
Pi10 3.30 (2.48 to 4.40), p<0.001 1.02 (1.02 to 1.02), p<0.001
*Model additionally adjusted for age, gender, current smoking status and scanner type. Parameter estimate is the fold change in BODE
index score for a 1 unit increase in radiological parameter. For normalized radiological parameters, airway disease measures and
emphysema values have been scaled and centred as follows: (value e mean)/SD. Hence a 1 unit increase in a normalized measure is 1
SD.
Pi10, 10 mm lumenal perimeter.
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An additional question raised is whether the relationship
between BODE and mortality is driven by the presence of
emphysema. Would emphysema itself be a better predictor of
mortality? Emphysema is associated with systemic inflamma-
tion, and interestingly, lung volume reduction surgery in
patients with upper lobe predominant emphysema results in
improved survival and a decrease in inflammatory mediators,
including tumour necrosis factor a and interleukin-8, as well as
an increase in a1-antitrypsin and BMI.22 23 Another question
raised by this analysis is whether the BODE index is the best
predictor of mortality among patients with an airway predom-
inant disease phenotype. Although longitudinal data will be
required to answer these questions definitively, previously
published data underscore the potential importance of CT
characterisation to identify subsets of COPD for specific thera-
pies. Emphysema distribution helps to identify suitable patients
for lung volume reduction therapy.23 We have also previously
demonstrated that QCT can be used to identify airway disease
predominant and emphysema predominant patient populations
with increased risk for exacerbations.2
A limitation to our analysis is that while emphysema and
airway disease measures were adjusted for scanner model, these
CT data were not corrected for variation within any particular
scanner model due to tube calibration or other factors. This is
a difficulty associated with performing QCT studies across
multiple sites and scanners. The methodology to do this is
currently being developed through the use of CT phantoms to
standardise images, but the algorithms to perform such correc-
tions are still being researched. Such corrections become even
more important when performing longitudinal studies in which
both intrascanner and interscanner variations may risk
obscuring signal detection.
In summary, our analyses demonstrate that radiological
indices of airway disease and emphysema influence BODE and
SGRQ. Airway disease, however, appears to be more closely
associated with higher SGRQ scores and emphysema appears to
be more closely associated with BODE. These analyses all
demonstrate the ability of QCT measures to relate to clinically
relevant outcomes and add to our ability to understand the
heterogeneity implicit to COPD. Future prospective studies will
allow us to better understand the predictive value of radiological
indices compared with composite indices such as SGRQ and
BODE.
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Journal club
Service targeting hard to reach tuberculosis patients in
London is cost effective
The incidence of tuberculosis in the UK is increasing, particularly in hard-to-reach groups such
as problematic drug users and homeless individuals. A ‘Find and Treat’ service, which provides
mobile radiography and case management support, has been operating in London since 2007.
This study assessed the cost effectiveness of the Find and Treat service for diagnosing and
managing hard to reach patients with tuberculosis.
Patients with active pulmonary tuberculosis screened or managed by the Find and Treat
service between 2007 and 2010 (48 identified by mobile screening, 188 referred for case
management support and 180 referred as lost to previous follow-up) were matched with 252
control patients who presented via London’s enhanced tuberculosis surveillance system.
A model was constructed based on various parameters such as the likelihood of completing
treatment and quality of life with untreated and treated tuberculosis. The Find and Treat
service was estimated to gain 220 quality-adjusted life years (QALYs) at a cost of £1.4 million/
year, estimating the incremental cost effectiveness ratio of the service at £6400/QALY. Making
less favourable assumptions in the model led to a higher cost per QALY, but the service was
still cost effective using NICE’s cut-off of £20 000e£30 000/QALY.
This study suggests that the London Find and Treat service is cost effective at identifying
and treating hardeto-reach individuals with tuberculosis. Similar initiatives may be rolled out
in other cities with a high prevalence of tuberculosis.
< Jit M, Stagg HR, Aldridge RW, et al. Dedicated outreach service for hard to reach patients with tuberculosis in London:
observational study and economic evaluation. BMJ 2011;343:d5376.
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